Efbemalenograstim alfa injection | China Drugs List

Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.

Company: Evive Biotechnology (Beijing) Ltd.
Medicine type: Biologic
Therapeutic area: Oncology
Indications recorded in the public source: To reduce infection presenting as febrile neutropenia in adults with nonmyeloid malignancies receiving myelosuppressive anticancer treatment likely to cause febrile neutropenia. Not for mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.
Indication source and scope: Source date(s): 2025, 2026. Indications transcribed from the public NHSA manufacturer submission; this is not verification of the complete current label.
Prescribing-information limitations: Complete official prescribing information obtained. Mainland China label. The full document is an older version; newer indications are supported by separate announcements or submissions.
China availability status: Historical Chinese approval verified; current continuous market availability has not been checked for every product.
Overseas status: Market-by-market verification pending.
Insurance classification: Included in national insurance (Category B)
Insurance edition: 2025 edition; effective 1 January 2026
Insurance restrictions: Restricted to patients who experienced severe neutropenia during previous chemotherapy.
Insurance period: 2026-01-01 to 2027-12-31
Insurance verification notes: Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.

Sources

Open the interactive record, public price references and discussions